Ibrutinib and venetoclax for first-line treatment of CLL

Arnon P. Kater^*, Mark David Levin, Carsten U. Niemann

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

8 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	New England Journal of Medicine
Vol/bind	381
Udgave nummer	8
Sider (fra-til)	788-789
Antal sider	2
ISSN	0028-4793
DOI	https://doi.org/10.1056/NEJMc1908754
Status	Udgivet - 2019

Adgang til dokumentet

@article{3473ac12d1134dd7b9ec6491a7818d9c,

title = "Ibrutinib and venetoclax for first-line treatment of CLL",

author = "Kater, {Arnon P.} and Levin, {Mark David} and Niemann, {Carsten U.}",

year = "2019",

doi = "10.1056/NEJMc1908754",

language = "English",

volume = "381",

pages = "788--789",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "8",

}

TY - JOUR

T1 - Ibrutinib and venetoclax for first-line treatment of CLL

AU - Kater, Arnon P.

AU - Levin, Mark David

AU - Niemann, Carsten U.

PY - 2019

Y1 - 2019

U2 - 10.1056/NEJMc1908754

DO - 10.1056/NEJMc1908754

M3 - Comment/debate

C2 - 31433936

AN - SCOPUS:85071332832

VL - 381

SP - 788

EP - 789

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 8

ER -